YY1

Across TCGA pan-cancer cohorts, YY1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated YY1 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher YY1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated YY1 expression acts as an unfavorable survival marker.

SARC, SCLC, and ESCA are the cancer types where YY1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	DFS	Median	All	0.038	0.611	<.001	12	view →
SCLC	DFS	Median	All	0.164	0.625	.018	12	view →
ESCA	DFS	Median	All	0.052	0.504	<.001	12	view →
LIHC	OS	Median	All	0.231	0.690	.011	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

YY1–SARC (DFS)

Open the SARC breakdown →